11 Papers
34 Citations
Qi Chen is an academic researcher from Second Military Medical University. The author has contributed to research in topics: Hematopoietic stem cell transplantation & Minimal residual disease. The author has an hindex of 4, co-authored 9 publications.
Chat about Author
Papers
A distinct glycerophospholipid metabolism signature of acute graft versus host disease with predictive value.
Yue Liu,Aijie Huang,Qi Chen,Xiaofei Chen,Yang Fei,Xiaoming Zhao,Weiping Zhang,Zhanying Hong,Zhenyu Zhu,Jianmin Yang,Chai Yifeng,Jian-Min Wang,Xiaoxia Hu +12 more
TL;DR: This work unraveled a comprehensive view of the molecular perturbations underlying the pathogenesis of the acute graft-versus-host disease with an initial investigation of a unique metabolic and transcriptomic network that may help identify aGvHD at an early stage and facilitate preemptive therapy.
23
Allogeneic hematopoietic stem cells transplantation improves the survival of intermediate-risk acute myeloid leukemia patients aged less than 60 years
Ying Zhang,Yimin Zhang,Qi Chen,Gusheng Tang,Weiping Zhang,Jianmin Yang,Jianmin Wang,Xiaoxia Hu +7 more
TL;DR: The results provide additional evidence that alloHSCT is preferential PRT in patients with intermediate-risk AML that are under the age of 60 years old in CR1, and patients who reached negative minimal residual disease after 2 cycles of consolidation could be further improved with an increased OS of 66% and RFS of 61%.
19
A clinical prediction model identifies a subgroup with inferior survival within intermediate risk acute myeloid leukemia.
Xiaoxia Hu,Bianhong Wang,Bianhong Wang,Qi Chen,Aijie Huang,W J Fu,Lixia Liu,Ying Zhang,Gusheng Tang,Hui Cheng,Xiong Ni,Lei Gao,Jie Chen,Li Chen,Weiping Zhang,Jianmin Yang,Shanbo Cao,Li Yu,Li Yu,Jianmin Wang +19 more
TL;DR: In this article, the authors performed targeted next generation sequencing analysis for 121 patients with 2017 European LeukemiaNet-defined intermediate risk acute myeloid leukemia (AML), revealing 122 mutated genes, with 24 genes mutated in > 10% of patients.
Impact of clinical utility of MRD assessment with different techniques on survival in acute B lymphoblastic leukemia.
Aijie Huang,Chongmei Huang,Gusheng Tang,Hui Cheng,Min Liu,Jing Ding,Shenglan Gong,Qi Chen,Weiping Zhang,Jianmin Yang,Jianmin Wang,Xiaoxia Hu +11 more
TL;DR: Flow-MRD can be used as a reliable prognostic marker for Ph− ALL patients and either by flow cytometry or quantitative reverse transcription-polymerase chain reaction at CR did not affect OS or DFS for Ph+ ALL.
9
Dynamic prediction of relapse in patients with acute leukemias after allogeneic transplantation: Joint model for minimal residual disease
Aijie Huang,Qi Chen,Yang Fei,Ziwei Wang,Xiong Ni,Lei Gao,Li Chen,Jie Chen,Weiping Zhang,Jianmin Yang,Jianmin Wang,Xiaoxia Hu +11 more
TL;DR: This data indicates that relapse remains the leading cause of treatment failure after allogeneic hematopoietic stem cell transplantation (alloHSCT) in leukemia and the need for serial monitoring to predict relapse risk.
4